Transforming patient recovery

with bioresorbable medical devices

About Polyganics

An innovative medical technology company developing and delivering unique medical devices to improve surgical outcomes and patient recovery

Technology Platform

Using state-of-the-art technology platforms to produce versatile bioresorbable and biocompatible synthetic polymers

Product Portfolio

Developing medical devices for use in targeted clinical applications to drive natural tissue repair and regeneration

Collagen Matrix Acquires Polyganics

The Investment Expands CMI’s Regenerative Medicine Portfolio,
R&D Capabilities and International Manufacturing Operations

Oakland, N.J., Groningen, The Netherlands, October 5, 2022 – Collagen Matrix, Inc. (“Collagen Matrix”), a global leader in regenerative medicine and a Linden Capital Partners (“Linden”) portfolio company, today announced the acquisition of Polyganics, B.V (“Polyganics”). Polyganics is a medical technology company that develops and manufactures bioresorbable medical devices. The acquisition expands Collagen Matrix’s portfolio of bioresorbable solutions and technology platforms for bone and tissue repair, unlocking new markets and clinical opportunities for the Company.